NuGen Medical Devices Inc.
NGMDF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.20 | 0.02 | 0.07 |
| FCF Yield | -30.08% | -35.60% | -58.25% | -28.62% |
| EV / EBITDA | -9.15 | -3.55 | -2.59 | -3.58 |
| Quality | ||||
| ROIC | -42.56% | -138.68% | -90.17% | -96.69% |
| Gross Margin | 51.68% | 49.74% | -363.11% | 67.00% |
| Cash Conversion Ratio | 0.90 | 0.72 | 0.38 | 0.58 |
| Growth | ||||
| Revenue 3-Year CAGR | 87.85% | 34.03% | 47.69% | – |
| Free Cash Flow Growth | 29.67% | -215.06% | 47.99% | -192.93% |
| Safety | ||||
| Net Debt / EBITDA | -3.74 | -1.00 | -1.73 | -0.81 |
| Interest Coverage | -3.09 | -6.51 | -4.74 | -6.27 |
| Efficiency | ||||
| Inventory Turnover | 1.52 | 0.80 | 9.19 | 3.52 |
| Cash Conversion Cycle | -139.01 | -1,278.14 | -123.38 | -6,129.90 |